CV-6209
Based on 1 Customer Validation
CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 100488-87-7
- Formula: C34H60ClN3O6
- Molecular Weight:642.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
platelet activating factor (PAF)[1]
In Vitro
CV-6209 inhibits [3H]serotonin release from rabbit platelets stimulated with PAF (30 nM)[1].
CV-6209 has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen[1].
CV-6209 (0.2-2 μM; pretreated for 30 min) inhibits PAF-induced MC degranulation in both LAD2 and hLMCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
CV-6209 (66 μg; i.v.) reduces asparaginase-induced hypersensitivity compared with nonpretreated, sensitized mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 100488-87-7
-
Appearance Solid
-
Molecular Weight 642.31
-
Formula C34H60ClN3O6
-
Color Off-white to light yellow
-
SMILES
CC[N+]1=CC=CC=C1CN(C(C)=O)C(OCC(OC)COC(NCCCCCCCCCCCCCCCCCC)=O)=O.[Cl-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (155.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8. [Content Brief]
[2]. Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017;27(3):161-168. [Content Brief]
[3]. Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352(3):541-51. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5569 mL | 7.7844 mL | 15.5688 mL | 38.9220 mL |
| 5 mM | 0.3114 mL | 1.5569 mL | 3.1138 mL | 7.7844 mL | |
| 10 mM | 0.1557 mL | 0.7784 mL | 1.5569 mL | 3.8922 mL | |
| 15 mM | 0.1038 mL | 0.5190 mL | 1.0379 mL | 2.5948 mL | |
| 20 mM | 0.0778 mL | 0.3892 mL | 0.7784 mL | 1.9461 mL | |
| 25 mM | 0.0623 mL | 0.3114 mL | 0.6228 mL | 1.5569 mL | |
| 30 mM | 0.0519 mL | 0.2595 mL | 0.5190 mL | 1.2974 mL | |
| 40 mM | 0.0389 mL | 0.1946 mL | 0.3892 mL | 0.9731 mL | |
| 50 mM | 0.0311 mL | 0.1557 mL | 0.3114 mL | 0.7784 mL | |
| 60 mM | 0.0259 mL | 0.1297 mL | 0.2595 mL | 0.6487 mL | |
| 80 mM | 0.0195 mL | 0.0973 mL | 0.1946 mL | 0.4865 mL | |
| 100 mM | 0.0156 mL | 0.0778 mL | 0.1557 mL | 0.3892 mL |